Literature DB >> 17606458

Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations.

Veselina Goranova-Marinova1, Stefan Goranov, Pavel Pavlov, Todorka Tzvetkova.   

Abstract

Serum levels of OPG and RANKL and their clinical correlations were analyzed in 66 newly-diagnosed patients with multiple myeloma (MM). RANKL and RANKL /OPG ratio were significantly increased in advanced clinical stages and high grade myeloma bone disease (MBD), while OPG showed a tendency to decrease. Renal failure modified the expression of OPG. RANKL and RANKL/OPG ratios are informative markers for myeloma tumor burden and MBD.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17606458     DOI： 10.3324/haematol.10943

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  16 in total

Review 1.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

2.  Soluble molecules and bone metabolism in multiple myeloma: a review.

Authors:  Gabriele Zoppoli; Enrico Balleari; Riccardo Ghio
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 3.  Reconstruction of multiple myeloma lesions around the pelvis and acetabulum.

Authors:  Vasileios I Sakellariou; Andreas F Mavrogenis; Olga Savvidou; Franklin H Sim; Panayiotis J Papagelopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-10-19

4.  Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients.

Authors:  Federico Biscetti; Giuseppe Straface; Silvia Giovannini; Angelo Santoliquido; Flavia Angelini; Luca Santoro; Carlo Filippo Porreca; Giovanni Pecorini; Giovanni Ghirlanda; Andrea Flex
Journal:  Hum Genet       Date:  2012-09-11       Impact factor: 4.132

5.  Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

Authors:  Wenjie He; Amitabha Mazumder; Tuere Wilder; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-05-16       Impact factor: 5.191

6.  Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Authors:  B Dalla Palma; D Guasco; M Pedrazzoni; M Bolzoni; F Accardi; F Costa; G Sammarelli; L Craviotto; M De Filippo; L Ruffini; P Omedè; R Ria; F Aversa; N Giuliani
Journal:  Leukemia       Date:  2015-09-30       Impact factor: 11.528

7.  Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.

Authors:  K Sfiridaki; C A Pappa; G Tsirakis; P Kanellou; M Kaparou; M Stratinaki; G Sakellaris; G Kontakis; M G Alexandrakis
Journal:  Mediators Inflamm       Date:  2011-09-18       Impact factor: 4.711

8.  Computational modeling of interactions between multiple myeloma and the bone microenvironment.

Authors:  Yan Wang; Peter Pivonka; Pascal R Buenzli; David W Smith; Colin R Dunstan
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

9.  Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients.

Authors:  Changlei Guo; Fudong Hu; Shaoli Zhang; Yakun Wang; Hengdao Liu
Journal:  Genet Mol Biol       Date:  2013-05-17       Impact factor: 1.771

Review 10.  Myeloma bone disease.

Authors:  Ralph D Sanderson; Joshua Epstein
Journal:  J Bone Miner Res       Date:  2009-11       Impact factor: 6.741
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.